Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)

October 29, 2026 updated by: Yongchun Song, Tianjin Medical University Cancer Institute and Hospital

This single-center study evaluates a novel body position and breath-holding device for lung cancer patients receiving stereotactic body radiation therapy. We will enroll 50 patients with single peripheral non-small cell lung cancer, compare tumor movement and radiation dose distribution with and without the device, to test if the device is safe, feasible and can improve treatment accuracy.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

For patients with peripheral non-small cell lung cancer receiving stereotactic body radiation therapy, respiratory motion often causes target volume deviation and compromises dose accuracy to tumors and nearby organs at risk. Current standard immobilization methods have limited ability to stabilize deep breathing patterns. This single-center translational study uses an integrated body position and breath-holding device, enrolling 50 eligible patients who will undergo 4DCT scans both with and without the device while keeping their clinical SBRT treatment plan unchanged. We will compare tumor motion amplitude, target coverage, conformity index and organ dose parameters between the two scanning states, to verify the device's feasibility, safety and value in improving treatment precision, providing clinical evidence for wider application in lung SBRT.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Tianjin, China, 300000
        • Tianjin Medical University Cancer Institute and Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Voluntarily participate and sign written informed consent
  2. Age ≥18 years, gender unlimited
  3. Clinically diagnosed with single peripheral lung cancer, assessed as suitable for SBRT
  4. Males or females of childbearing age willing to take contraceptive measures during the trial
  5. Female of childbearing age must have a negative pregnancy test within 7 days before treatment, and all patients use adequate contraception during treatment and for 4 weeks after

Exclusion Criteria:

  1. Intolerant or unwilling to receive the integrated respiratory suppression and positioning immobilization device for radiotherapy localization.
  2. Currently participating or planning to participate in other clinical trials.
  3. Refuse or be unable to sign the informed consent form for this trial.
  4. Patients with central or ultra-central lung cancer.
  5. Patients planned to receive SBRT for multiple pulmonary lesions.
  6. Patients assessed by the investigators of this trial as unsuitable for SBRT treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Single Arm - Novel Respiratory Immobilization

All enrolled patients receive 4DCT with and without the device

A novel immobilization device used for respiratory motion management during lung stereotactic body radiation therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean respiratory motion amplitude of GTV and organs at risk (OARs) measured on 4DCT before and after abdominal pressure immobilization
Time Frame: through study completion, an average of 1 year

Respiratory motion amplitude (maximum displacement) of gross tumor volume (GTV) and organs at risk (OARs) will be contoured and extracted from pre-abdominal-pressure 4DCT and post-abdominal-pressure 4DCT. The difference in motion amplitude between the two states will be compared to evaluate the feasibility and effectiveness of the novel abdominal pressure positioning membrane for lung SBRT.

through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Conformity index (CI) of SBRT planning target volume (PTV)
Time Frame: At the time of SBRT plan design, prior to treatment delivery

CI of PTV calculated from SBRT dose distribution after abdominal pressure immobilization

At the time of SBRT plan design, prior to treatment delivery
Coverage of planning target volume (PTV)
Time Frame: At the time of SBRT plan design, prior to treatment delivery

PTV coverage calculated from SBRT dose distribution after abdominal pressure immobilization

At the time of SBRT plan design, prior to treatment delivery
Maximum relative dose at 2 cm outside the PTV boundary (D2cm)
Time Frame: At the time of SBRT plan design, prior to treatment delivery

Percentage of maximum dose at the region 2 cm outside PTV boundary on SBRT plan

At the time of SBRT plan design, prior to treatment delivery
Volume of normal ipsilateral lung receiving ≥20Gy,15Gy,10Gy and 5Gy (V20,V15, V10, V5)
Time Frame: At the time of SBRT plan design, prior to treatment delivery

Dose-volume histogram parameters of normal treated lung from abdominal-pressure SBRT plan

At the time of SBRT plan design, prior to treatment delivery
Maximum dose (Dmax) to organs at risk including spinal cord, heart and esophagus
Time Frame: At the time of SBRT plan design, prior to treatment delivery

Dmax of OARs derived from SBRT dose plan under abdominal pressure immobilization

At the time of SBRT plan design, prior to treatment delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 10, 2025

Primary Completion (Estimated)

July 31, 2028

Study Completion (Estimated)

July 31, 2028

Study Registration Dates

First Submitted

October 19, 2026

First Submitted That Met QC Criteria

October 29, 2026

First Posted (Actual)

November 4, 2026

Study Record Updates

Last Update Posted (Actual)

November 4, 2026

Last Update Submitted That Met QC Criteria

October 29, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • bc20261997

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

This is an exploratory feasibility study, and no public sharing of individual patient data is planned.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.